Crofelemer

DRUG11 trials

Conditions

Breast AdenocarcinomaBreast CancerChronic Diarrhea of Unknown OriginColonic DiseasesDiarrheaDiarrhea With HIVGastrointestinal DiseaseHER2-positive Breast Cancer

Phase 2

A Study of Crofelemer to Treat Diarrhea Irritable Bowel Syndrome

CompletedNCT00101725

Bausch Health Americas, Inc.Colonic Diseases, Diarrhea, Gastrointestinal Disease +1

Start: 2004-12-31End: 2005-11-30Updated: 2019-11-25

Diarrhea Predominant Irritable Bowel Syndrome in Females

CompletedNCT00461526

Bausch Health Americas, Inc.Irritable Bowel Syndrome

Start: 2006-10-31End: 2007-12-31Updated: 2019-11-25

Diarrhea Prevention and Prophylaxis With Crofelemer in HER2 Positive Breast Cancer Patients

CompletedNCT02910219

Sandra SwainBreast Cancer

Start: 2017-01-31End: 2020-11-23Updated: 2022-10-24

Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib

CompletedNCT03094052

University of California, San FranciscoBreast Adenocarcinoma, HER2-positive Breast Cancer, Stage IIA Breast Cancer AJCC v6 and v7 +6

Start: 2018-10-09End: 2022-10-31Updated: 2025-06-26

A Phase 2, Placebo-Controlled, Randomized, Double-Blind Study of 2 Doses of Crofelemer for the Treatment of adult patients with Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon in continuity (CIC)

RecruitingCTIS2024-511994-31-00

Napo Therapeutics S.p.A.Short Bowel Syndrome and Intestinal Failure (SBS-IF) without colon-in-continuity (CIC

Start: 2025-03-10Target: 22Updated: 2025-12-23

Phase 3

A Double-Blind, Randomized, Placebo-Controlled, Multicenter Study to Assess the Efficacy and Safety of Orally Administered SP-303 for the Treatment of Diarrhea in Acquired Immunodeficiency Syndrome (AIDS) Patients

CompletedNCT00002408

Shaman PharmaceuticalsDiarrhea, HIV Infections

Target: 300Updated: 2005-06-24

Safety and Tolerability of Crofelemer for HIV-Associated Diarrhea

CompletedNCT01374490

Bausch Health Americas, Inc.Diarrhea With HIV, HIV Enteropathy

Start: 2011-06-07End: 2012-10-31Updated: 2020-08-31

Phase 4

Yield of Diagnostic Tests and Effects of Crofelemer for Chronic Idiopathic Diarrhea In Non-HIV Patients

CompletedNCT03898856

The University of Texas Health Science Center, HoustonChronic Diarrhea of Unknown Origin

Start: 2019-04-01End: 2025-01-30Updated: 2026-02-12

Crofelemer for Functional Diarrhea

TerminatedNCT04486326

Beth Israel Deaconess Medical CenterDiarrhea

Start: 2020-08-20End: 2022-09-23Updated: 2026-03-10

Unknown Phase

Double-Blind Placebo-Controlled Study Comparing the Combination of 15% SP-303 Gel With Acyclovir Versus Acyclovir Alone for the Treatment of Recurrent Herpes Simplex Virus (HSV) Infections in Subjects With Acquired Immunodeficiency Syndrome (AIDS)

CompletedNCT00002186

Shaman PharmaceuticalsHerpes Simplex, HIV Infections

Target: 400Updated: 2005-06-24

SP-303T Applied to the Skin of Patients With Herpes Simplex Virus (HSV) Infection and AIDS Who Have Not Had Success With Acyclovir

CompletedNCT00002310

Shaman PharmaceuticalsHerpes Simplex, HIV Infections

Updated: 2005-06-24

Related Papers

Abstract PO3-13-01: ONTARGET: Phase 3 randomized, double-blind, placebo-controlled trial evaluating crofelemer for the prophylaxis of diarrhea in adult patients with solid tumors receiving targeted therapies with or without standard chemotherapy

Cancer Research2024-05-02

HALT-D: a randomized open-label phase II study of crofelemer for the prevention of chemotherapy-induced diarrhea in patients with HER2-positive breast cancer receiving trastuzumab, pertuzumab, and a taxane.

2022-10-256 citations

Abstract P5-18-09: Halt-d: A randomized open label phase 2 study of crofelemer for the prevention of chemotherapy induced diarrhea (cid) in patients with breast cancer receiving trastuzumab, pertuzumab, and a taxane

Cancer Research2022-02-151 citations

HALT-D: A Phase II Evaluation of Crofelemer for the Prevention and Prophylaxis of Diarrhea in Patients With Breast Cancer on Pertuzumab-Based Regimens.

2016-08-2712 citations